Microbial components such as lipopolysaccharide (LPS) bind to Toll-like receptors (TLRs) and activate innate and inflammatory responses. Responses to LPS and other microbial components are limited by the activation of negative feedback mechanisms that reduce responsiveness to subsequent LPS exposure, often termed LPS tolerance. Our laboratory has previously shown that calcineurin, a phosphatase known for its activation of T cells via NFAT, negatively regulates the TLR pathway in macrophages; consequently, calcineurin inhibitors (FK506 and cyclosporin A) mimic TLR ligands in activating the TLR pathway, NF-kB, and associated innate and inflammatory responses. This study investigated the physiological consequences of calcineurin inactivation for LPS-induced inflammatory responses in vitro and in vivo using two models: calcineurin inhibition by FK506 (tacrolimus) and myeloid cell-specific calcineurin deletion. Activation of dendritic cells and macrophages with FK506 in vitro was shown to induce a state of reduced responsiveness to LPS (i.e. a form of LPS tolerance). Similarly, macrophages from FK506-treated mice or from mice in which the calcineurin B1 (CnB1) subunit was conditionally knocked out in myeloid cells were found to have diminished LPS-induced inflammatory responses. In addition, mice with CnB1-deficient myeloid cells and mice undergoing FK506 treatment showed improved survival and recovery when challenged with high doses of systemic LPS compared to controls. These results demonstrate that inactivation of calcineurin in macrophages and other myeloid cells by inhibition or deletion can induce a form of LPS tolerance and protect the host from LPS toxicity in vivo.
INTRODUCTION
The mammalian innate immune system uses a variety of strategies to recognize and defend against invading pathogens. The recognition of 'microbial non-self' is thought to be a universal strategy of innate immunity as it is found in all studied multicellular organisms. Mammalian Toll-like receptors (TLRs), homologous to Toll-1 anti-fungal receptor in Drosophila, are expressed by many cell types, including dendritic cells and macrophages, which express an abundant array of TLRs and play a key role in innate immunity by binding pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS). 1, 2 Lipopolysaccharide, also called endotoxin, is a component of the cell membrane of Gram-negative bacteria and is one of the most potent activators of innate immune responses. Lipopolysaccharide binds to TLR4, leading to activation of downstream pathways that can activate nuclear factor (NF)-kB and other transcription factors such as IRF3. 3, 4 It is well proven that NF-kB is a major and essential activator of inflammatory processes, inducing expression and secretion of cytokines (TNF-a, IL-12, IL-1a, IL-1b, IL-6), adhesion molecules (ELAM-1, VCAM-1, ICAM-1), chemokines (IL-8, MCP-1, RANTES), enzymes (matrix metalloproteinases, cyclooxygenase-2 [COX-2], inducible nitric oxide synthase), and other mediators. 5 Innate immune responses are highly regulated. For example, to minimize harmful consequences of excessive response to bacterial infection, such as septic shock, LPS-induced production of inflammatory mediators is limited by the activation of negative feedback mechanisms that lead to unresponsiveness or 'tolerance' to subsequent LPS exposure (often referred to as endotoxin tolerance or LPS tolerance). When animals and humans are exposed to even small doses of LPS, inhibitory mechanisms are initiated that cause them to become less susceptible to the lethal effects of subsequent exposure to LPS. 6, 7 One study showed that rats that had been pretreated with endotoxin survived a challenge dose of endotoxin that was 100% lethal for naïve rats. 8 This diminished susceptibility was shown to be associated with an absent or decreased cellular response to LPS. Priming of macrophages or dendritic cells with LPS can render them unresponsive or 'tolerant' for up to several days following initial exposure, [9] [10] [11] leaving them unable to respond to subsequent exposure to LPS and other TLR ligands, sometimes termed 'homotolerance' and 'heterotolerance', respectively. 8, 12, 13 Additionally, macrophages from patients who have survived exposure to endotoxin during infection have decreased or absent response to endotoxin exposure in vitro, 14, 15 which has also been shown for macrophages from healthy volunteers injected with LPS. 16 Calcineurin, also called protein phosphatase 2B (PP2B), was originally discovered as a major calmodulin-binding protein in the brain over 20 years ago. 17 Calcineurin was subsequently determined to be the only known Ca 2þ and calmodulin-activated serine/threonine phosphatase, and it is highly conserved from yeast to man. 18 Calcineurin is composed of a catalytic subunit, CnA (69-62 kDa), and a regulatory subunit, CnB (18) (19) . The catalytic unit CnA exists as three isoforms in vertebrates, of which CnAa and CnAb are ubiquitous expressed, while CnAg is only expressed in testis and brain. There are two CnB isoforms: CnB1 is ubiquitously expressed, while CnB2 is only found in testis. [19] [20] [21] The discovery of the effectiveness of calcineurin inhibitors cyclosporin A (CsA) and tacrolimus (FK506) as immunosuppressants has revolutionized transplantation. [22] [23] [24] [25] [26] The identification of calcineurin as the target of these drugs 27 led to the discovery that calcium flux-activated calcineurin is responsible for the dephosphorylation and activation of NFAT, required for the activation of T-cell responses. [28] [29] [30] More recently, the activation of NFAT by calcineurin has also been shown to be involved in B-cell responses. 31 Currently, patients undergoing transplantation often receive calcineurin inhibitors as part of their immunosuppression regimen to prevent rejection. Calcineurin inhibitors are also used as treatment for inflammatory skin diseases and autoimmune disease. [32] [33] [34] In addition to the central role of calcineurin in activating adaptive immune responses, our laboratory has demonstrated that calcineurin is involved in regulating the TLR pathway in some cell types, including monocytes, macrophages, astrocytes, and fibroblasts. 35, 36 However, in these cells, calcineurin plays a negative regulatory role; calcineurin inhibitors have activating, pro-inflammatory effects, in contrast to the inhibitory effects seen in T cells. Calcineurin inhibitors do not block LPS-induced cytokine expression in macrophages; instead, in the absence of LPS or other stimuli, they induce expression of a number of proinflammatory macrophage effector genes. We have shown that treatment of peritoneal macrophages with CsA or FK506 activates NF-kB, mRNA expression of pro-inflammatory genes TNF-a, IL-1a, IL-1b, IL-12, and iNOS and secretion of TNF-a and IL-12 when given with IFN-g. 35 Also, calcineurin inhibitors and siRNA knockdown of calcineurin activated the intermediates of the IL-1R/TLR-mediated NF-kB activation pathway (both MyD88-dependent and MyD88-independent) in macrophages. Conversely, expression of a constitutively-active form of calcineurin was shown to block macrophage activation by TLR ligands. The results of knockout and immunoprecipitation experiments suggest that TLR-proximal signaling components (some of the TLR and the adapter proteins MyD88 and TRIF) are the key direct or indirect targets of calcineurin. 36 The pro-inflammatory effects of calcineurin inhibitors predict several possible physiological consequences of calcineurin inhibition in vivo. Our previously-published in vitro findings that calcineurin inhibitors activate the TLR pathway in macrophages and other innate immune cells suggest that inhibition of calcineurin in these cells in vivo could lead to an on-going systemic inflammatory response or to sensitization to LPS and/or pathogens. Alternatively, calcineurin inhibitors might induce a form of LPS tolerance in macrophages and dendritic cells. Studies reported here show the latter to be the case. Exposure to calcineurin inhibitors in vitro or in vivo induces tolerance to LPS in macrophages and dendritic cells, and in vivo studies show that prolonged inactivation of calcineurin in myeloid cells by inhibition or deletion leads to protection against LPS-induced toxicity. These findings suggest that treatment with calcineurin inhibitors may suppress innate and inflammatory responses as well as adaptive immune responses.
MATERIALS AND METHODS

Animals
The CD11b-cre þ mice were generously provided by Jean Vacher. 37 The CD11b-cre line used in the crosses contains $4 copies of the cre transgene integrated on the Y chromosome under control of the CD11b promoter. Cnb1 f/Á mice were generously provided by Gerald Crabtree. 38 These mice carry on one chromosome the Cnb1 f allele, in which the Cnb1 gene is flanked by loxP sites, and on the other a deletion of the Cnb1 gene, i.e. a null Cnb1 allele (Cnb1 Á ). Then CD11b-cre þ ;Cnb1 f/ Á mice were generated by breeding Cnb1 f/Á mice with CD11b-cre þ mice. Because only males carry the transgene, all experiments involving CD11b-cre þ ;Cnb1 f/Á mice included only male mice. Screening of Cnb1 tail DNA was done with the following primers, CNB15 0 ÁB, 5 0 -CAATGCAGTCCGCTGTAGTTC-3 0 ; LOXP3 0 AMP/ SEQ, 5 0 -GACAGCTATACAGAGAAACCCTG-3 0 ; LOXP3 0 AMP, 5 0 -AGCCTCCACATACACAGATAC-3 0 , and where necessary, Cre recombinase transgenic screening using the following primers -forward, 5 0 -AATGCTTCTGTCCGTTTGC-3 0 and reverse, 5 0 -CGGCAACACCATTTTTTCTG-3 0 . The Cnb1 þ product, 189 bp, Cnb1 f , 286 bp, Cnb1 Á , 168 bp, and cre, 617 bp. All CD11b-cre þ ;Cnb1 f/Á mice used in experiments were screened to confirm that peritoneal macrophages, which are 80-90% positive for CD11b surface expression, were negative for CnB1 protein expression using Western blot or PCR. For use in FK506 injection experiments, C57BL/6J female mice were obtained from Jackson Laboratories. All mice used were age matched, and were generally 6-8 weeks old. All animal studies were approved by the Administrative Panel for Laboratory Animal Care.
Reagents
Lyophilized FK506 powder (LC Labs) was reconstituted in either 100% ethanol for in vitro treatments or 80% ethanol, 20% cremaphor solution for in vivo treatments and stored at -20 C. For injection, the FK506 solution was diluted into a vehicle (75% propanediol, 25% water) to 0.2-1.0 mg/ml. The vehicle control solution for in vivo experiments consisted of ethanol and cremaphor mixture diluted into 75% propanediol, 25% water. All FK506 and vehicle solutions were tested for LPS contamination using the Limulus Amebocyte Lysate (LAL) test (Cambrex Bio Science Walkersville). Lipopolysaccharide lyophilized powder (List Biological Labs) was dissolved and diluted in phosphate-buffered saline (PBS). As lethality varied among lots of LPS, when a lethal dose of LPS was desired for challenge, each lot of LPS was tested for LD 50 before each experiment by injecting naïve mice with varying doses of LPS (5-10 mice per dose group) and assessing survival. The lowest dose that yielded 80-100% death was used for the LPS challenge dose in the subsequent experiment.
Lipopolysaccharide challenge
All mice were observed every hour for the first 24-48 h following the lethal LPS challenge. Mice were observed for characteristics of LPS toxicity (ocular exudates, diarrhea, increased respiratory rate) as well as moribund status (inability to sustain body temperature, ataxia or tremors, diaphragmatic breathing). In order to assess recovery, mice were given a score from 0-3 based on ambulation as an indication of overall health status: 0, unable to walk; 1, take steps to walk; 2, able to walk quickly but not run; and 3, able to run/normal ambulation.
FK506 treatment protocol and experimental groups
Mice (C57BL/6J) received a subcutaneous injection of FK506 (5 mg/kg) or vehicle control solution of the same volume every 24 h for 3 days (three injections total). The third injection was given simultaneously with an intraperitoneal (i.p.) injection of LPS challenge lethal dose (10-20 mg/kg) or a high sub-lethal dose (5-10 mg/kg). Another group of naïve mice were given a sub-lethal i.p. injection of LPS (1.0 mg/kg) on the second injection day, 24 h before the LPS challenge injection, as the positive control. All mice were observed as indicated above.
Isolation of peritoneal macrophages and bone marrow-derived dendritic cells
Peritoneal macrophages were isolated as previously described. 35 Bone marrow was obtained from femurs taken from C57BL/6J mice and flushed with medium. Dendritic cells were differentiated using a protocol adapted from Lutz et al. 39 with the following modifications: Day 0: bone marrow cells were plated at 2 Â 10 6 cells/plate in 9 ml of standard medium with 20 ng/ml of GM-CSF. Day 3: 1 ml of media with 100 ng GM-CSF was added to the plate to a final concentration of 10 ng/ml of GM-CSF. Day 6: 5 ml were removed from each plate and centrifuged to pellet floating cells. Floating cells were resuspended in medium with 20 ng/ml GM-CSF and added back to the plate to a final concentration of 10 ng/ml GM-CSF. Day 8: repeat steps for day 6. Day 10: floating cells (dendritic cells) were gently removed from each plate and plated for future experiments. Each mouse (2 femurs) yielded $80-90 Â 10 6 floating cells which were 60-80% CD11c positive by FACS (data not shown).
In vitro assay for LPS tolerance induction
The mouse macrophage cell line RAW264.7, BMDC, and peritoneal macrophages were plated at 1 Â 10 6 cells/ well in standard medium and treated with either solvent, 0.1 mg/ml LPS or FK506 at 1 mg/ml or 10 mg/ml and incubated at 37 C for 12-24 h. Supernatants were removed and cells were washed three times with PBS, treated with medium alone or 2 mg/ml LPS for tolerance induction and incubated for another 12-24 h. Supernatants were assayed for IL-12 and TNF-a using sandwich ELISA.
Antibodies
Capture and biotinylated detection antibodies against mouse cytokines used in ELISA were purchased from BD-Pharmingen except anti-IL-12p40 C15.6 coating antibody, which was purified in our laboratory from hybridoma culture. The HRP-linked antibodies used on Western blots were purchased from Amersham Biosciences, and Anti-CnB1 antibody from Sigma.
Cytokine ELISA
To quantify the levels of cytokines present in cell supernatants, plates were coated with 1-2 mg/ml of primary antibody. Cytokines of interest were then detected with 0.5 mg/ml of biotinylated antibody, followed by addition of streptavidin-HRP conjugate. Colorimetric reactions were generated using ABTS (BD-Pharmingen) at optical densities of 405 nm.
Cytometric bead array
In some experiments, the levels of TNF-a in serum samples and supernatants were measured using a cytometric bead array (CBA) from BD-Pharmingen according to the manufacturer's instructions. Flow cytometry was performed on a Coulter Epics XL-MCL machine.
Cytokine RT-PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and a 1 mg aliquot was reverse transcribed using murine leukemia virus (MLV) reverse transcriptase (Gibco). Resulting cDNA was subsequently amplified using the following specific primers: (TNF-a forward, 5 0 -TTCTATGGCCCAGACCCTCA-3 0 , reverse, 5 0 -TCC CAGGTATATGGGCTCATA-3 0 ; IL-1b forward, 5 0 -GG CTGCTTCCAAACCTTTGA-3 0 , reverse, 5 0 -GAAGAC ACGGATTCCATGGT-3 0 ; IL-12p40 forward, 5 0 -TGGC CAATGTGGGAGCTGGA-3 0 , reverse, 5 0 -TTGGTGCTT CACACTTCAGGA-3 0 ; and GAPDH forward, 5 0 -TCGT GGAGTCTACTGGCGT-3 0 , reverse, 5 0 -GCCTGCTTCA CCACCTTCT-3 0 ). PCR conditions were optimized and varied for each primer pair.
Nuclear extracts and EMSA
Nuclear extracts were prepared as previously described. 35 Radiolabeling of NF-kB oligonucleotides with [g-32 P]-ATP, EMSA, and supershift assays were performed, according to the manufacturer's protocols (Promega).
Immunoblotting
Whole cell lysates were prepared after various incubation conditions. Cells were washed in ice-cold PBS and suspended in ice-cold RIPA lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, 2 mg/ml pepstatin, 1 mM dithiothreitol, 1 mM sodium fluoride, 10 mM sodium orthovanadate). Samples were agitated for 30 min, and then centrifuged for 8 min at 8,000 rpm at 4 C. Equal amounts of protein were separated by SDS-PAGE on 10-12% acrylamide gels. The proteins were then transferred to a PVDF membrane (Amersham). The membrane was placed in blocking buffer (PBS, 0.5% Tween-20, 5% milk powder) and subsequently incubated with primary antibody and HRPconjugated secondary antibody, and detected with ECL chemiluminescence kit (Amersham).
RESULTS
FK506 induces production of inflammatory cytokines and activates NF-kB in dendritic cells
Previously published findings from this laboratory showed that the calcineurin inhibitors FK506 and CsA activate NF-kB in macrophages leading to the expression and secretion of pro-inflammatory mediators. 35 This finding has now been extended to mouse bone marrow-derived dendritic cells (BMDCs) treated with FK506. Assays for secreted protein (Fig. 1A) and RNA (Fig. 1B) demonstrated the induction of the inflammatory mediators IL-12, TNF-a, IL-1, and COX-2 in BMDCs treated with FK506. The activation of pro-inflammatory mediators seen in these results is supported by the finding that FK506 activates NF-kB in BMDCs (Fig. 1C ) as previously shown in macrophages. 35, 36 FK506 induces a form of LPS tolerance in macrophages and dendritic cells in vitro In addition to the initial induction of pro-inflammatory gene expression, the activation of TLR4 by LPS induces multiple negative feedback mechanisms that act on TLR-activated signaling pathways, which render cells tolerant to subsequent exposure to LPS. 40, 41 As FK506 and LPS both induce inflammatory mediators via TLR-mediated signaling pathways, 35, 36 whether FK506 is also able to induce a similar LPS tolerant state was examined. Lipopolysaccharide tolerance in macrophages has been thought to be most closely associated with decreased TNF production, 7, 8 whereas in dendritic cells, tolerance is better associated with decreased IL-12 production; 13 therefore, macrophage TNF responses and dendritic cell IL-12 responses were assessed. Both peritoneal macrophages ( Fig. 2A ) and the macrophage cell line RAW264.7 (Fig. 2B ) showed decreased production of TNF-a in response to LPS after being pretreated 20 h earlier with either FK506 or LPS. Similar effects of pretreatment with FK506 or LPS were observed for BMDC IL-12 production (Fig. 2C) . These impaired responses constitute a form of LPS tolerance. Cell counts obtained when supernatants were harvested confirmed that diminished responses were not due to differences in cell viability (data not shown). Macrophages from mice treated with FK506 exhibit tolerance to LPS in vitro Macrophages and peripheral blood monocytes from septic patients have been shown to have a decreased response to LPS when stimulated in vitro; 7 therefore, we investigated whether macrophages from FK506-treated mice also exhibit a similar decreased response, reflecting a form of in vivo LPS tolerance. As expected, resident peritoneal macrophages from mice that had received a prior injection of LPS produced significantly less IL-12 and TNF-a in response to an in vitro treatment with LPS or FK506 compared to macrophages from mice receiving only PBS (Fig. 3A) . Significantly, macrophages from mice given FK506 injections over 3 days also produced lower amounts of IL-12 and TNF-a in response to an in vitro treatment with LPS or FK506 compared to those from mice receiving only the vehicle control (Fig. 3A ). In addition, NF-kB activation was reduced in macrophages from FK506-treated mice compared to cells from the vehicle-treated mice (Fig. 3B ).
FK506 protects against LPS-induced toxicity in vivo
The phenomenon of LPS tolerance has also been observed in vivo; it contributes to various processes in human and animal subjects that can be either protective (i.e. reducing septic shock) or detrimental (i.e. reducing protective immunity to pathogens) to the host. To determine whether the induction of tolerance to LPS by FK506 could be protective against LPS-induced toxicity in an animal model, mice were injected with either an FK506 regimen or one low dose of LPS (1 mg/kg) and subsequently challenged with either a lethal (15-20 mg/kg) or sub-lethal (7.5-10 mg/kg) dose of LPS. The mice were then observed for signs of LPS toxicity in a blind study for up to 48 h post LPS challenge. Mice showing signs of morbidity were euthanized. Mice pretreated with FK506 or LPS had a significantly better survival rate when challenged with the lethal dose of LPS than did those that received vehicle only (Fig. 4A ). In addition, mice pretreated with FK506 or LPS exhibited improved recovery and reduced illness, as determined by a qualitative score based on health status, from a sublethal dose of LPS compared to mice given vehicle only (Fig. 4B ).
Macrophages deficient in CnB1 exhibit a form of LPS tolerance in vitro
Mice that are genotypically CD11b-cre þ ;Cnb1 f/Á , generated to have myeloid cells deficient in the CnB1 subunit, are fertile and show no gross abnormalities. Approximately 30% of all CD11b-cre þ ;Cnb1 f/Á adult mice possessed CnB1-deficient peritoneal macrophages, as determined by PCR ( Fig. 5A) or Western blot (Fig. 5B) ; therefore, mice were screened for macrophage CnB1 expression prior to their assignment to experimental groups. All mice designated as CnB1-deficient in the data shown here were CD11b-cre þ ;Cnb1 f/Á mice confirmed to have CnB1-deficient peritoneal macrophages by Western blot or PCR. CnB1-deficient peritoneal macrophages from CD11b-cre þ ;Cnb1 f/Á mice showed decreased activation by LPS in vitro.
Macrophages deficient in CnB1 showed decreased TNFa secretion (Fig. 5C ) and IL-12 secretion (Fig. 5D ) compared to wild-type when stimulated with LPS. Also, as would be predicted, CnB1-deficient macrophages produced little or no cytokines in response to calcineurin inhibition by FK506 treatment unlike wild-type macrophages ( Fig. 5C,D) . In contrast, cells from the CD11bcre þ ;Cnb1 f/Á mice with CnB1-positive macrophages behaved similar to wild-type cells (data not shown).
There was no significant difference in the cell counts from CnB1-deficient macrophages compared to wildtype cells (data not shown).
Mice with CnB1-deficient macrophages are less susceptible to LPS-induced toxicity in vivo
The data demonstrating tolerance to LPS in CnB1deficient macrophages presented in Figure 5 along with reported findings showing that LPS tolerance in vivo is mediated by macrophages 42 suggest that the ability of injected FK506 to protect mice from LPS-induced toxicity and mortality ( Fig. 4 ) was due to the induction of a form of LPS tolerance secondary to calcineurin inactivation in the macrophages of these mice. This led us to investigate whether the deletion of Cnb1 (which would reduce calcineurin activity) in macrophages of mice would also yield protection from LPS in vivo.
To test this hypothesis, both wild-type and CD11bcre þ ;Cnb1 f/Á mice with CnB1-deficient macrophages (designated CnB1-deficient mice) were challenged with a lethal dose (20 mg/kg) of LPS and observed in a blind study for 24 h post LPS challenge. Mice showing signs of morbidity were euthanized. The CnB1-deficient mice showed a better survival rate when challenged with lethal doses of LPS compared to wild-type control mice (Fig. 6A ). In addition, sera from CnB1-deficient mice challenged with LPS showed significantly lower levels of TNF-a compared to sera from wild-type mice (Fig. 6B) .
DISCUSSION
Although the role of calcineurin in T-cell activation and adaptive immunity is well established, little has been reported about its role in innate immune responses. Our laboratory previously reported data showing that calcineurin inhibitors activate NF-kB and innate and inflammatory responses in mouse peritoneal macrophages, the WEHI-3 mouse myelomonocytic cell line, primary mouse astrocytes, and the L929 fibroblast cell line. 35 More recently, we have extended these findings to mouse macrophage cell line RAW264.7, human monocytic cell lines, U937 and THP-1, 36 and bone marrow derived dendritic cells (this study). Results described in this report show that inactivation of calcineurin with the calcineurin inhibitor, FK506, or by cell-specific deletion of CnB1, induces a state of reduced responsiveness to LPS, reminiscent of LPS tolerance in macrophages and dendritic cells in vitro. In addition, FK506-treated mice and mice with CnB1-deficient macrophages exhibit an LPStolerant phenotype and are partially protected from LPS-induced toxicity.
In the induction of LPS tolerance, initial activation of the TLR pathway leads to gene activation followed by activation of negative feedback pathways and subsequent unresponsiveness to LPS. In our in vitro studies, macrophages and dendritic cells became less responsive to LPS following pretreatment with FK506, as revealed by reduced NF-kB activation, induction of pro-inflammatory gene expression, and cytokine production. Also, macrophages from FK506-treated mice showed diminished NF-kB activation in response to LPS, and decreased production of TNF and IL-12 in response to LPS as well as FK506. Similarly, the CnB1deficient macrophages showed decreased production of TNF in response to LPS. Collectively, these results indicate that reduced calcineurin activity results in an LPS tolerant state in macrophages. These findings are consistent with earlier reports that calcineurin inhibitor treatment leads to decreased inflammatory responses. Dendritic cells differentiated in the presence of CsA showed decreased expression of co-stimulatory molecules, associated with a reduction in nuclear translocation of NF-kB, 43 and also reduced IL-12 production following activation. 44 In addition to the in vitro findings, our in vivo studies showed that treatment with FK506 improves both survival and recovery in mice challenged with LPS. As expected, mice pretreated with LPS, which is known to induce LPS tolerance strongly, exhibited the most protection. Also, mice with CnB1-deficient macrophages had improved survival and decreased serum TNF after challenge with a lethal dose of LPS. Although we had previously shown that reduced calcineurin activity mediated by calcineurin inhibitors or siRNA leads to an initial increase in NF-kB activation and associated induction of pro-inflammatory cytokines, 35, 36 the persistent inactivation of calcineurin by inhibition or deletion, as in the models presented in this report, also results in the induction of tolerance to subsequent exposure to LPS, similar to the effects of LPS itself.
Many mechanisms contributing to LPS tolerance have been described 7, 40, 41 and are likely candidates for FK506-induced tolerance to LPS, as FK506 activates the same signaling pathways downstream of TLR. 36 Interestingly, the macrophages from LPS-treated mice showed decreased cytokine production in response to in vitro exposure to FK506 as well as to LPS; thus, FK506 and LPS induce tolerance to each other. These observations suggest that the mechanism(s) of tolerance seen here reflect negative feedback pathways activated via the TLR signaling pathways, which are triggered by both LPS and calcineurin inhibitors. As we reported recently, 36 calcineurin inhibitors mimic TLR ligands in that they act at TLR-proximal steps to activate both MyD88-dependent and MyD88-independent signaling pathways, leading to activation of NF-kB and other transcription factors. The finding that deletion of calcineurin in macrophages also induces tolerance to both LPS and FK506 supports the conclusion that the induction of tolerance by FK506 is a result of its inhibition of calcineurin, and subsequent activation of the TLR signaling pathways. The incidence of sepsis has recently been estimated to be 751,000 cases per year with a mortality of approximately 30% in the US. 45 Sepsis is also a leading cause of death in infants and children with 42,000 cases per year in the US. 46 A recent study reported that in early sepsis, during what is called systemic inflammatory response syndrome (SIRS), endotoxin was detected in the blood of 52.1% of patients. 47 Patients with sepsis have been found to have high levels of circulating inflammatory mediators such as TNF and IL-6. 7 Those who survive the initial SIRS develop a compensatory immune de-activation with profound reduction in immune response, sometimes referred to as immunoparalysis. 48 Although there are murine models that better emulate the environment of sepsis compared to LPS-induced shock, [49] [50] [51] it is still believed that endotoxin tolerance is a good model for the numerous alterations in cellular responses that occur in the immunoparalysis of sepsis and SIRS. 52 It has been recently reported that induction of endotoxin tolerance can enhance survival in sepsis. 53 Our findings show that inactivation of calcineurin by inhibition or deletion in murine macrophages and dendritic cells in vitro or macrophages in vivo induces decreased responsiveness to LPS. Inactivation of calcineurin in vivo also provides partial protection against LPS-induced morbidity and mortality in mice. These results suggest that the modulation of calcineurin activity affects survival during endotoxin exposure and possibly sepsis. Further studies in specific sepsis models might reveal a use for FK506 and other calcineurin inhibitors in decreasing mortality from sepsis.
Currently, patients undergoing transplantation often receive calcineurin inhibitors as part of their immunosuppression regimen to prevent rejection, and calcineurin inhibitors are also used to treat inflammatory disorders, such as autoimmune disease 33, 34 and inflammatory skin disease. 32 The efficacy of CsA and FK506 in these situations has been assumed to reflect their potent inhibition of T-cell activation, which also has been the explanation for a common detrimental side effect of calcineurin inhibitors -the increased risk of opportunistic infections. 54 It has also been shown that SIRS-associated LPS tolerance also can cause increased susceptibility to infection. 55, 56 This study has demonstrated the induction of a form of tolerance to LPS in macrophages and dendritic cells by the calcineurin inhibitor, FK506, in in vitro and in vivo models. In a similar way, treatment with calcineurin inhibitors, as occurs in many patients today, may induce alterations in innate immune responses in addition to suppression of adaptive immune responses. Lipopolysaccharide tolerance in its classical form (induced by prior in vivo exposure to LPS) can increase resistance to infection, 57, 58 likely due to increases in some types of innate immune mechanisms such as pathogen binding and antigen presentation. 59 However, LPS tolerance has also been shown to reduce expression of many proinflammatory mediators, 59 thus reducing the benefit of these responses in the host. Calcineurin inactivation, as shown in this report, creates a form of LPS tolerance characterized by reduced production of pro-inflammatory mediators IL-12 and TNF, which may contribute to increased susceptibility to infections in patients treated with calcineurin inhibitors. These findings support the need to discover additional immunosuppressants, especially inhibitors that specifically target T cells, to avoid alterations in protective innate immune responses. 
